FDA looks to boost biosimilars to lower drug costs

The Trump administration is moving to speed up approvals of copycat biologic drugs as a way to lower health costs and boost an underused market. Why it matters: Efforts to elevate biosimilars have been thwarted by unfavorable placement on formularies and doctors' refusal to switch patients to the look-alike treatments. Now, the Food and Drug Administration is easing some requirements around studies that biosimilar makers conduct to compare the...